0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Non-Hodgkin’s Lymphoma (NHL) -Epidemiology Forecast to 2028
Published Date: March 2019
|
Report Code: DELV-Epid-326
Home | Market Reports | Health | Health Conditions
Non Hodgkins Lymphoma Epidemiology Forecast to 2028

Non-Hodgkin’s Lymphoma (NHL) -Epidemiology Forecast to 2028

Code: DELV-Epid-326
Report
March 2019
50 Pages
Delveinsight
Region: Global,
Description
Table of Content
Tables & Figures

DelveInsight's "Non-Hodgkin’s Lymphoma (NHL) - Epidemiology Forecast, 2028” report provides a comprehensive analysis of the Non-Hodgkin’s Lymphoma (NHL) epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2028.

Markets Covered
• United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2016-2028

Non-Hodgkin’s Lymphoma (NHL) Epidemiology
The epidemiology section covers the historical, current as well as forecasted epidemiology for Non-Hodgkin’s Lymphoma (NHL) in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders’ views are also taken into account to provide a deep understanding of the Non-Hodgkin’s Lymphoma (NHL) outlook. It also includes the explanation of changing trends of epidemiology outlining the Non-Hodgkin’s Lymphoma (NHL) scenario.

Non-Hodgkin’s Lymphoma (NHL) Epidemiology Segmentation
The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Non-Hodgkin’s Lymphoma (NHL) thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.

Report Scope
• The report covers detailed overview of Non-Hodgkin’s Lymphoma (NHL) explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
• The Non-Hodgkin’s Lymphoma (NHL) Report assesses the disease risk and burden and highlights the unmet needs
• It also helps to recognize the growth opportunities in the 7MM with respect to the patient population

Key strengths
• 10 Year Forecast
• 7MM Coverage
• Total Cases in Non-Hodgkin’s Lymphoma (NHL)

Key assessments
• Patient Segmentation in Non-Hodgkin’s Lymphoma (NHL)
• Non-Hodgkin’s Lymphoma (NHL) Risk & Burden
• Factors driving growth in a specific Non-Hodgkin’s Lymphoma (NHL) patient population

1. Report Introduction
2. Non-Hodgkin’s Lymphoma (NHL) Epidemiology Overview at a Glance
2.1. Patient Share Distribution of Non-Hodgkin’s Lymphoma (NHL) in 2016
2.2. Patient Share Distribution of Non-Hodgkin’s Lymphoma (NHL) in 2028
3. Disease Background and Overview: Non-Hodgkin’s Lymphoma (NHL)
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Non-Hodgkin’s Lymphoma (NHL) in 7MM
4.3. Total Prevalent/ Incident Patient Population of Non-Hodgkin’s Lymphoma (NHL) in 7MM – By Countries
5. Epidemiology of Non-Hodgkin’s Lymphoma (NHL) by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Non-Hodgkin’s Lymphoma (NHL)
5.1.3. Sub-Type Specific cases of the Non-Hodgkin’s Lymphoma (NHL) *
5.1.4. Sex- Specific Cases of the Non-Hodgkin’s Lymphoma (NHL)*
5.1.5. Diagnosed Cases of the Non-Hodgkin’s Lymphoma (NHL)
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Non-Hodgkin’s Lymphoma (NHL)
5.4.3. Sub-Type Specific cases of the Non-Hodgkin’s Lymphoma (NHL)*
5.4.4. Sex- Specific Cases of the Non-Hodgkin’s Lymphoma (NHL)*
5.4.5. Diagnosed Cases of the Non-Hodgkin’s Lymphoma (NHL)
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Non-Hodgkin’s Lymphoma (NHL)
5.5.3. Sub-Type Specific cases of the Non-Hodgkin’s Lymphoma (NHL)*
5.5.4. Sex- Specific Cases of the Non-Hodgkin’s Lymphoma (NHL)*
5.5.5. Diagnosed Cases of the Non-Hodgkin’s Lymphoma (NHL)
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Non-Hodgkin’s Lymphoma (NHL)
5.6.3. Sub-Type Specific cases of the Non-Hodgkin’s Lymphoma (NHL)*
5.6.4. Sex- Specific Cases of the Non-Hodgkin’s Lymphoma (NHL)*
5.6.5. Diagnosed Cases of the Non-Hodgkin’s Lymphoma (NHL)
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Non-Hodgkin’s Lymphoma (NHL)
5.7.3. Sub-Type Specific cases of the Non-Hodgkin’s Lymphoma (NHL)*
5.7.4. Sex- Specific Cases of the Non-Hodgkin’s Lymphoma (NHL)*
5.7.5. Diagnosed Cases of the Non-Hodgkin’s Lymphoma (NHL)
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Non-Hodgkin’s Lymphoma (NHL)
5.8.3. Sub-Type Specific cases of the Non-Hodgkin’s Lymphoma (NHL)*
5.8.4. Sex- Specific Cases of the Non-Hodgkin’s Lymphoma (NHL)*
5.8.5. Diagnosed Cases of the Non-Hodgkin’s Lymphoma (NHL)
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Non-Hodgkin’s Lymphoma (NHL)
5.9.3. Sub-Type Specific cases of the Non-Hodgkin’s Lymphoma (NHL)*
5.9.4. Sex- Specific Cases of the Non-Hodgkin’s Lymphoma (NHL)*
5.9.5. Diagnosed Cases of the Non-Hodgkin’s Lymphoma (NHL)
6. Unmet Needs of the Non-Hodgkin’s Lymphoma (NHL)
7. Appendix
8. Report Methodology
8.1. Sources
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
*Indication Specific

List of Tables

Table 1: Total Prevalent/Incident Cases of the Non-Hodgkin’s Lymphoma (NHL) in 7MM
Table 2: Total Prevalent/Incident Cases of the Non-Hodgkin’s Lymphoma (NHL) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Non-Hodgkin’s Lymphoma (NHL) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Non-Hodgkin’s Lymphoma (NHL) in United States (2016-2028)*
Table 5: Sex- Specific Cases of the Non-Hodgkin’s Lymphoma (NHL) in United States (2016-2028)*
Table 6: Diagnosed Cases of the Non-Hodgkin’s Lymphoma (NHL) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Non-Hodgkin’s Lymphoma (NHL) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Non-Hodgkin’s Lymphoma (NHL) in Germany (2016-2028) *
Table 9: Sex- Specific Cases of the Non-Hodgkin’s Lymphoma (NHL) in Germany (2016-2028) *
Table 10: Diagnosed Cases of the Non-Hodgkin’s Lymphoma (NHL) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Non-Hodgkin’s Lymphoma (NHL) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Non-Hodgkin’s Lymphoma (NHL) in France (2016-2028) *
Table 13: Sex- Specific Cases of the Non-Hodgkin’s Lymphoma (NHL) in France (2016-2028) *
Table 14: Diagnosed Cases of the Non-Hodgkin’s Lymphoma (NHL) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Non-Hodgkin’s Lymphoma (NHL) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Non-Hodgkin’s Lymphoma (NHL) in Italy (2016-2028) *
Table 17: Sex- Specific Cases of the Non-Hodgkin’s Lymphoma (NHL) in Italy (2016-2028) *
Table 18: Diagnosed Cases of the Non-Hodgkin’s Lymphoma (NHL) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Non-Hodgkin’s Lymphoma (NHL) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Non-Hodgkin’s Lymphoma (NHL) in Spain (2016-2028) *
Table 21: Sex- Specific Cases of the Non-Hodgkin’s Lymphoma (NHL) in Spain (2016-2028) *
Table 22: Diagnosed Cases of the Non-Hodgkin’s Lymphoma (NHL) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Non-Hodgkin’s Lymphoma (NHL) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Non-Hodgkin’s Lymphoma (NHL) in UK (2016-2028) *
Table 25: Sex- Specific Cases of the Non-Hodgkin’s Lymphoma (NHL) in UK (2016-2028) *
Table 26: Diagnosed Cases of the Non-Hodgkin’s Lymphoma (NHL) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Non-Hodgkin’s Lymphoma (NHL) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Non-Hodgkin’s Lymphoma (NHL) in Japan (2016-2028) *
Table 29: Sex- Specific Cases of the Non-Hodgkin’s Lymphoma (NHL) in Japan (2016-2028) *
Table 30: Diagnosed Cases of the Non-Hodgkin’s Lymphoma (NHL) in Japan (2016-2028)

List of Figures

Figure 1: Total Prevalent/Incident Cases of the Non-Hodgkin’s Lymphoma (NHL) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Non-Hodgkin’s Lymphoma (NHL) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Non-Hodgkin’s Lymphoma (NHL) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Non-Hodgkin’s Lymphoma (NHL) in United States (2016-2028)*
Figure 5: Sex- Specific Cases of the Non-Hodgkin’s Lymphoma (NHL) in United States (2016-2028)*
Figure 6: Diagnosed Cases of the Non-Hodgkin’s Lymphoma (NHL) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Non-Hodgkin’s Lymphoma (NHL) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Non-Hodgkin’s Lymphoma (NHL) in Germany (2016-2028) *
Figure 9: Sex- Specific Cases of the Non-Hodgkin’s Lymphoma (NHL) in Germany (2016-2028) *
Figure 10: Diagnosed Cases of the Non-Hodgkin’s Lymphoma (NHL) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Non-Hodgkin’s Lymphoma (NHL) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Non-Hodgkin’s Lymphoma (NHL) in France (2016-2028) *
Figure 13: Sex- Specific Cases of the Non-Hodgkin’s Lymphoma (NHL) in France (2016-2028) *
Figure 14: Diagnosed Cases of the Non-Hodgkin’s Lymphoma (NHL) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Non-Hodgkin’s Lymphoma (NHL) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Non-Hodgkin’s Lymphoma (NHL) in Italy (2016-2028) *
Figure 17: Sex- Specific Cases of the Non-Hodgkin’s Lymphoma (NHL) in Italy (2016-2028) *
Figure 18: Diagnosed Cases of the Non-Hodgkin’s Lymphoma (NHL) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Non-Hodgkin’s Lymphoma (NHL) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Non-Hodgkin’s Lymphoma (NHL) in Spain (2016-2028) *
Figure 21: Sex- Specific Cases of the Non-Hodgkin’s Lymphoma (NHL) in Spain (2016-2028) *
Figure 22: Diagnosed Cases of the Non-Hodgkin’s Lymphoma (NHL) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Non-Hodgkin’s Lymphoma (NHL) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Non-Hodgkin’s Lymphoma (NHL) in UK (2016-2028) *
Figure 25: Sex- Specific Cases of the Non-Hodgkin’s Lymphoma (NHL) in UK (2016-2028) *
Figure 26: Diagnosed Cases of the Non-Hodgkin’s Lymphoma (NHL) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Non-Hodgkin’s Lymphoma (NHL) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Non-Hodgkin’s Lymphoma (NHL) in Japan (2016-2028) *
Figure 29: Sex- Specific Cases of the Non-Hodgkin’s Lymphoma (NHL) in Japan (2016-2028) *
Figure 30: Diagnosed Cases of the Non-Hodgkin’s Lymphoma (NHL) in Japan (2016-2028)

SELECT A FORMAT
Added to Cart

Electronic (PDF)
$3250
This license allows only one user to access the PDF.

Electronic (PDF)
$6500
This license allows all the users of an enterprise residing in one location to access the PDF

Electronic (PDF)
$9750
This license allows all the employees of an enterprise to access the PDF.
Add to Cart
Buy Now (10% Discount)
OUR CUSTOMER
Bioinformatics Barcelona

RELATED REPORTS

Global and United States Tick borne Encephalitis Inactivated Vaccine Market Insights Forecast to 2027
Global and United States Tick-borne Encephalitis Inactivated Vaccine Market Insights, Forecast to 2027

120 Pages
Type: Report
Code: QYRE-Auto-34O6484
Sun Sep 05 00:00:00 UTC 2021

Add to Cart

Global and Japan Dasatinib Drugs Market Insights Forecast to 2027
Global and Japan Dasatinib Drugs Market Insights, Forecast to 2027

120 Pages
Type: Report
Code: QYRE-Auto-26C6576
Sun Sep 05 00:00:00 UTC 2021

Add to Cart

Global and United States Blood Glucose Device SMBG Market Insights Forecast to 2027
Global and United States Blood Glucose Device (SMBG) Market Insights, Forecast to 2027

120 Pages
Type: Report
Code: QYRE-Auto-34D6519
Sun Sep 05 00:00:00 UTC 2021

Add to Cart

Global and Japan Acute Lymphocytic Lymphoblastic Leukemia Treatment Market Size Status and Forecast 2021 2027
Global and Japan Acute Lymphocytic/Lymphoblastic Leukemia Treatment Market Size, Status and Forecast 2021-2027

120 Pages
Type: Report
Code: QYRE-Auto-11I6837
Sun Sep 05 00:00:00 UTC 2021

Add to Cart